https://scholars.lib.ntu.edu.tw/handle/123456789/511635
標題: | Safety of rifabutin replacing rifampicin in the treatment of tuberculosis: A single-centre retrospective cohort study | 作者: | JUNG-YIEN CHIEN Chien S. Huang S. CHONG-JEN YU |
公開日期: | 2014 | 卷: | 69 | 期: | 3 | 起(迄)頁: | 790-796 | 來源出版物: | Journal of Antimicrobial Chemotherapy | 摘要: | Objectives: The safety of rifabutin replacing rifampicin among adults having rifampicin-related adverse reactions (ARs) during the treatment of tuberculosis remains unknown. Methods: From June 2006 to June 2010, a total of 2868 newly treated tuberculosis patients without HIV infection in a referral hospital were screened in this retrospective cohort study. Results: Among the screened patients, a total of 221 (8%) patients who received rifabutin replacing rifampicin were included. Of these patients, 158 (72%) tolerated rifabutin during treatment, but 47 (21%) and 16 (7%) experienced mild and severe rifabutin-related ARs (including neutropenia, severe hepatitis and uveitis), respectively, and needed to discontinue rifabutin. Those having previous rifampicin-related arthralgia, dermatological events and cholestasis had a higher AR recurrence rate (60%, 23% and 9%, respectively) than others (5% for hepatitis and gastrointestinal intolerance and 0% for flu-like syndrome, neutropenia and others; P<0.01). Multivariate logistic regression analysis showed that females (OR 3.35; 95% CI 1.06-10.56; P0.04) and patients with hepatitis virus B (HBV) or hepatitis C virus (HCV) coinfection (OR 3.72; 95% CI 1.19-11.67; P=0.02) were at a higher risk of rifabutin-related severe ARs. No development of new drug resistance and no relapse of tuberculosis were found during 2 years of follow-up. Conclusions: Rifabutin replacing rifampicin was well tolerated in most adults who had rifampicin-related ARs. Females and those with HCV or HBV coinfection were more prone to rifabutin-related severe ARs and required more cautious monitoring. ? The Author 2013. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84894042593&doi=10.1093%2fjac%2fdkt446&partnerID=40&md5=0d259c3980c738862650900a144af1ed https://scholars.lib.ntu.edu.tw/handle/123456789/511635 |
ISSN: | 0305-7453 | DOI: | 10.1093/jac/dkt446 | SDG/關鍵字: | rifabutin; rifampicin; tuberculostatic agent; adult; aged; chronic hepatitis C; cohort analysis; complication; Drug-Related Side Effects and Adverse Reactions; female; hepatitis B; human; male; middle aged; retrospective study; tuberculosis; very elderly; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Rifabutin; Rifampin; Tuberculosis |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。